Cyclo Therapeutics Inc
NASDAQ:CYTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pernod Ricard SA
OTC:PDRDF
|
FR |
Cyclo Therapeutics Inc
Cash from Operating Activities
Cyclo Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
Cash from Operating Activities
-$22.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-48%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$19B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
14%
|
|
Cyclo Therapeutics Inc
Glance View
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
See Also
What is Cyclo Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-22.5m
USD
Based on the financial report for Sep 30, 2024, Cyclo Therapeutics Inc's Cash from Operating Activities amounts to -22.5m USD.
What is Cyclo Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-48%
Over the last year, the Cash from Operating Activities growth was -54%. The average annual Cash from Operating Activities growth rates for Cyclo Therapeutics Inc have been -13% over the past three years , -33% over the past five years , and -48% over the past ten years .
